NCT07195656 (EVANESCE-II) is a NA clinical trial of Device Group in Overactive Bladder (OAB), sponsored by FemPulse Corporation.

Who is sponsoring NCT07195656?

NCT07195656 is sponsored by FemPulse Corporation.

What drugs are being tested in NCT07195656?

Interventions in NCT07195656: Device Group, Medication Group.

What condition does NCT07195656 study?

NCT07195656 studies Overactive Bladder (OAB).

Is NCT07195656 still recruiting?

NCT07195656 is currently recruiting now. Last updated 6 February 2026.

Last reviewed 2026-02-06 · How we verify

NCT07195656: EVANESCE-II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

Recruiting now NA Last updated 6 February 2026

What this trial tests

NA trial testing Device Group in Overactive Bladder (OAB) in 151 participants. Currently enrolling.

Timeline

30 September 2025

Primary endpoint
31 May 2027

31 December 2027

Quick facts

Lead sponsor	FemPulse Corporation
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	151
Start date	30 September 2025
Primary completion	31 May 2027
Estimated completion	31 December 2027
Sites	15 locations across United States

Drugs / interventions tested

Device Group
Medication Group

Conditions studied

Overactive Bladder (OAB) — all drugs for Overactive Bladder (OAB) →

Sponsor

FemPulse Corporation

Who can join

21 and older, female only, with Overactive Bladder (OAB). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study to evaluate the safety and effectiveness of FemPulse System

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Overactive Bladder (OAB)

Currently open trials in the same condition.

NCT07193407 — INOPASE - Performance and Safety Study of a Personalised SNM System · NA · recruiting
NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
NCT07025044 — Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrus · recruiting
NCT07371000 — Early Detection of OAB and Elimination of Negative Impact on Quality of Life · NA · recruiting
NCT07025642 — Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes · NA · recruiting

Other FemPulse Corporation trials

Trials by the same sponsor.

NCT06885099 — Ease of Use Study of the FemPulse System · NA · completed
NCT06347380 — Usability Study of the FemPulse System · NA · completed
NCT04001426 — Pilot Phase for an Acute Evaluation of a Non-Implantable Electrical Continence Device · NA · completed
NCT03784170 — FemPulse Therapy for Overactive Bladder in Women · NA · completed
NCT03874637 — FemPulse Therapy First-in-Human Experience · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07195656 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by FemPulse Corporation
Last refreshed: 6 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07195656.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing